Add like
Add dislike
Add to saved papers

Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients.

Neuroleptic medication was reintroduced to 15 patients who had suffered an episode of neuroleptic malignant syndrome (NMS). Thirteen (87%) were eventually able to take neuroleptics again, indicating that they did not have an inherent intolerance. The authors analyzed the ability of patients to tolerate rechallenge according to the time of reintroduction after resolution of a previous episode and the relative neuroleptic potency and dosage compared with the initial episode. Successful rechallenge was highly significantly related to the time that had elapsed following resolution of the previous episode. The choice of a neuroleptic lower in potency and dosage than that which precipitated the original NMS episode was not significantly related to successful outcome.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app